Using Methotrexate for Sarcoidosis: A Treatment Overview

Methotrexate is the most widely used steroid-sparing medication for sarcoidosis, prescribed when prednisone alone is not enough or when its side effects become intolerable. A 2025 randomized trial published in the New England Journal of Medicine found that methotrexate performed just as well as prednisone for pulmonary sarcoidosis, with lung function improving by a similar margin in both groups. That trial has started to reshape thinking about where methotrexate fits, potentially moving it from its traditional second-line role toward something closer to a first-choice option for certain patients.

How Methotrexate Tamps Down Sarcoidosis

Sarcoidosis is driven by overactive immune cells that clump into tiny clusters of inflammation called granulomas. These can lodge in the lungs, heart, eyes, skin, nervous system, or virtually any organ. Methotrexate interferes with the folate pathway that immune cells need to proliferate, and it also nudges the body to release more adenosine, a molecule that quiets inflammation. The net effect is a broad dampening of the immune overreaction behind granuloma formation.¹ This dual action on both cell growth and inflammatory signaling is part of why methotrexate works across so many different organ manifestations of the disease.

The Case for Pulmonary Sarcoidosis

The lungs are the organ most frequently affected by sarcoidosis, and the strongest evidence for methotrexate comes from this setting. The landmark trial mentioned above, called TOP STEP, randomized patients with pulmonary sarcoidosis to receive either prednisone or methotrexate as initial treatment. After 24 weeks, the prednisone group improved their lung function (measured by forced vital capacity, or FVC) by about 6.75 percentage points, while the methotrexate group improved by about 6.11 percentage points. The difference between the two groups was small enough for the researchers to declare methotrexate noninferior to prednisone.² In practical terms, this means patients whose doctors are worried about the weight gain, bone loss, or blood sugar problems that come with long-term prednisone now have a reasonable alternative right from the start.

Real-world data from clinical practice tells a similar story. A single-center study tracking 60 patients on methotrexate for pulmonary sarcoidosis found that roughly 82% were classified as responders on imaging, and those responders saw measurable improvements in quality of life. The study also confirmed a strong steroid-sparing effect, meaning patients were able to cut back their prednisone doses significantly once methotrexate was on board.³

One important caveat is that methotrexate tends to work more slowly than prednisone. The background section of the TOP STEP trial itself acknowledges that methotrexate has a slower onset of action.² This means that for patients with rapidly progressive disease or severe symptoms at diagnosis, doctors may still reach for prednisone first and add methotrexate as steroid-tapering becomes the priority.

Reducing the Steroid Burden

The most compelling practical reason to use methotrexate is to get patients off high-dose steroids. Prednisone controls sarcoidosis inflammation effectively, but the long-term price is steep: osteoporosis, diabetes, cataracts, muscle wasting, mood disturbance, and weight gain, among others. Methotrexate allows many patients to taper their steroid dose substantially or stop it entirely, while achieving comparable rates of disease control.⁴

A large retrospective study of patients on either methotrexate or azathioprine for sarcoidosis found that prednisone doses dropped by an average of about 6 mg per year during treatment. Among patients who completed at least one year on either drug, 70% had reduced their daily prednisone by at least 10 mg.⁵ For someone taking 30 or 40 mg of prednisone daily, that kind of reduction can mean the difference between tolerating treatment and developing serious steroid side effects.

Methotrexate Beyond the Lungs

Sarcoidosis is not just a lung disease, and methotrexate has been studied across several of its organ manifestations. The evidence varies in quality from organ to organ, but the overall picture is encouraging.

Ocular Sarcoidosis

Sarcoidosis involving the eyes often causes a severe form of uveitis (inflammation inside the eye) that can threaten vision. A study of patients with sarcoid-associated panuveitis found that after starting methotrexate, 90% of eyes had preserved or improved visual acuity. Average visual acuity improved from 20/62 to 20/40. The steroid-sparing results were dramatic: every patient who had been on oral corticosteroids was able to reduce the dose, and 86% stopped oral steroids completely. The mean steroid dose dropped from about 27 mg to just 1.5 mg per day.⁶ The study also noted that five of six eyes that had been too inflamed for cataract surgery became stable enough on methotrexate to undergo the procedure, with all five gaining better vision afterward.

Cardiac Sarcoidosis

Cardiac sarcoidosis is one of the most dangerous manifestations of the disease because granulomas in the heart muscle can cause arrhythmias, heart block, or heart failure. Evidence here is growing but still largely comes from observational studies rather than large trials. A retrospective study of 61 newly diagnosed cardiac sarcoidosis patients found that those started on methotrexate, prednisone, or a combination had similar rates of metabolic response on PET imaging, with about 71% of all patients responding after roughly six months. During two years of follow-up, the methotrexate group had a numerically lower rate of serious cardiac events compared to prednisone alone, though the difference was not statistically significant.⁷

A separate cohort study described a strategy where patients received a short course of high-dose prednisone followed by transition to methotrexate for maintenance. This approach initially reduced or eliminated active inflammation on PET imaging in 88% of patients and fully resolved it in 60%.⁸ This “bridge and maintain” strategy, where prednisone puts out the initial fire and methotrexate keeps it out, has become a common approach at specialized sarcoidosis centers.

Neurosarcoidosis

When sarcoidosis involves the brain, spinal cord, or nerves, treatment often becomes more complicated. Case reports going back decades have described patients with neurosarcoidosis who failed prednisone but responded to methotrexate.⁹ A more systematic comparison involving 40 neurosarcoidosis patients found that those on methotrexate had a relapse rate of 47%, compared to 79% in patients on mycophenolate mofetil. The median time to relapse was also longer with methotrexate: 28 months versus 11 months for mycophenolate.¹⁰ That said, a 47% relapse rate is still high, reflecting the difficulty of treating neurosarcoidosis in general, regardless of the drug used.

Another study following 19 patients with neurosarcoidosis on methotrexate found that after one year, patients had improved clinically and on brain MRI, and most were maintained on low-dose prednisone alongside low-dose methotrexate.¹¹

How Methotrexate Stacks Up Against Other Second-Line Agents

Methotrexate is not the only steroid-sparing drug used for sarcoidosis. Azathioprine and mycophenolate mofetil are the main alternatives. Head-to-head data is limited, but the comparisons that do exist tend to favor methotrexate on safety grounds, with effectiveness looking broadly similar across these agents.

The clearest advantage methotrexate has over its competitors is a lower infection risk. A Swedish study using real-world data estimated that patients starting methotrexate had about a 43% lower risk of infectious disease at six months compared to those starting azathioprine.¹² The large retrospective comparison mentioned earlier also found significantly more infections in the azathioprine group (about 35% versus 18% with methotrexate), though both drugs produced similar improvements in lung function and steroid reduction.⁵

For cardiac sarcoidosis specifically, a comparative effectiveness study found that starting mycophenolate mofetil instead of methotrexate nearly doubled the risk of infection, while azathioprine also trended toward higher infection rates. The risk of serious cardiac outcomes was similar across all three drugs.¹³ This pattern of similar effectiveness but better safety has helped make methotrexate the default second-line choice at many sarcoidosis clinics.

Side Effects and Monitoring Challenges

Methotrexate is generally well tolerated at the doses used for sarcoidosis, but it comes with its own set of concerns. In the real-world pulmonary study described earlier, about 32% of patients experienced some adverse event, most commonly gastrointestinal problems like nausea or mouth sores. Only about 7% had to stop the drug because of side effects.³ Folic acid supplementation, commonly prescribed alongside methotrexate, can reduce these gastrointestinal complaints, though that particular study noted tolerable side effect profiles even without folic acid.

Liver toxicity is a more serious concern, and monitoring for it in sarcoidosis patients turns out to be surprisingly tricky. Because sarcoidosis itself frequently involves the liver, many patients already have abnormal liver enzyme levels that have nothing to do with drug toxicity. A study focused specifically on this problem found that standard liver function tests were not useful for predicting which sarcoidosis patients would develop methotrexate-related liver damage. More than half the patients who did develop liver toxicity on biopsy never had elevated AST levels in the preceding year. The researchers concluded that liver biopsy remains an important screening tool for long-term methotrexate users with sarcoidosis, since blood tests alone can miss the problem.¹⁴ That said, a large six-year cohort study tracking over 600 sarcoidosis patients on methotrexate found that moderate liver enzyme elevation occurred in fewer than 2% of patients, suggesting clinically significant hepatotoxicity is uncommon even if it is hard to detect by routine blood work.¹⁵

A rarer but particularly confusing side effect is methotrexate-induced pneumonitis, where the drug itself triggers lung inflammation. In a patient being treated for pulmonary sarcoidosis, new breathing problems and abnormal imaging could easily be mistaken for a sarcoidosis flare rather than a drug reaction. A documented case in a cardiac sarcoidosis patient showed that PET imaging revealed intense lung uptake that resolved completely after stopping methotrexate, confirming the drug rather than the disease was responsible.¹⁶ This possibility is worth knowing about because the treatment for it (stopping methotrexate) is the opposite of the treatment for a sarcoidosis flare (increasing immunosuppression).

What Happens When You Stop Methotrexate

One of the open questions for any chronic sarcoidosis treatment is whether you can eventually stop the drug without the disease coming roaring back. A recent prospective study followed 12 cardiac sarcoidosis patients who had responded well to methotrexate after an average treatment duration of about 45 months. After stopping the drug, only one patient (about 8%) experienced a cardiac relapse, presenting with a dangerous heart rhythm problem roughly six months after discontinuation. Four others (33%) had extracardiac relapses, meaning sarcoidosis flared in other organs but not the heart. The remaining patients had no relapses over roughly two years of follow-up.¹⁷ These results suggest durable remission is possible after a prolonged course, though the risk of relapse outside the heart is not trivial, and the one cardiac relapse was life-threatening. Most clinicians still approach discontinuation cautiously, with close monitoring afterward.

Genetics and Why Some Patients Respond Differently

Not everyone with sarcoidosis responds to methotrexate the same way, and genetics appears to play a role. A preliminary study examined variations in the gene for TNF-alpha, a key inflammatory molecule, and found that certain genetic variants were linked to distinct response patterns. Patients could be grouped into early responders, late responders, and non-responders based on lung function testing. Those carrying specific TNF-alpha gene variants at positions -308 and -857 had markedly different likelihoods of responding quickly versus slowly. For example, patients with the -308 GG genotype had roughly three times the chance of being early responders compared to late responders. Combined genotyping of both positions could distinguish late responders from the other groups with 85% sensitivity.¹⁸

This is still early-stage work, but it points toward a future where genetic testing might help predict who will benefit quickly from methotrexate, who will need to wait longer for results, and who might be better served by a different drug from the start. For now, the practical takeaway is that if methotrexate does not seem to be working after a few months, that does not necessarily mean it has failed. Some patients are genetically programmed to be slower responders, and a longer trial may be warranted before switching.

Combining Methotrexate With Biologic Drugs

For patients with refractory sarcoidosis that does not respond adequately to methotrexate alone, biologic medications like infliximab (a TNF-alpha blocker) may be added. In this setting, methotrexate plays a secondary but important role. Infliximab is a protein-based drug, and the immune system can develop neutralizing antibodies against it over time, rendering it ineffective. A case report of a patient with fulminant sarcoidosis documented exactly this scenario: the patient’s disease spiraled dangerously after developing antibodies to infliximab. The authors emphasized that concomitant low-dose methotrexate can help prevent these neutralizing antibodies from forming, preserving the biologic drug’s effectiveness.¹⁹

This dual purpose of methotrexate, as both an independent anti-inflammatory agent and a protector of biologic drug efficacy, is borrowed from rheumatology, where the same strategy has been standard practice for decades in treating conditions like rheumatoid arthritis. In cardiac sarcoidosis specifically, one cohort study found that patients who needed adalimumab (another TNF-alpha blocker) added to their methotrexate regimen experienced improved or resolved inflammation on PET imaging in 84% of cases.⁸ The combination approach has become an important escalation strategy for patients who do not fully respond to methotrexate or steroids alone.

Dosing Practicalities

Methotrexate for sarcoidosis is taken once a week, not daily, which is a point of confusion for patients who are used to medications taken every day. The recommended starting dose is typically between 5 and 15 mg per week, often beginning at the lower end and increasing as tolerated.¹ It can be given as pills or as a subcutaneous injection; the injectable form sometimes causes fewer gastrointestinal side effects because it bypasses the stomach. Most patients are advised to take folic acid on the days they are not taking methotrexate to reduce side effects like nausea, mouth ulcers, and fatigue, though as noted earlier, some patients tolerate methotrexate acceptably even without it.

Regular blood work is standard practice while on methotrexate, typically including a complete blood count and liver enzymes every one to three months. As discussed in the monitoring section, liver enzyme tests have real limitations in sarcoidosis patients specifically, so some experts advocate for periodic liver imaging or biopsy in patients on long-term therapy, particularly those who have been on the drug for more than two years.¹⁴ Alcohol should be minimized or avoided because it compounds the liver stress. Women of childbearing age need reliable contraception because methotrexate can cause serious birth defects, and the drug should be stopped well in advance of any planned pregnancy.

1
PubMed. Molecular mechanism of action and pharmacokinetic properties of methotrexate
2
PubMed. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate
3
PubMed Central. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study
4
PubMed Central. The Long-Term Use of Methotrexate Monotherapy as a Steroid-Sparing Agent for Patients With Pulmonary Sarcoidosis
5
PubMed. Methotrexate vs azathioprine in second-line therapy of sarcoidosis
6
PubMed. Methotrexate treatment for sarcoid-associated panuveitis
7
Journal of Nuclear Cardiology. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis
8
PubMed Central. Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis
9
PubMed Central. Neurosarcoidosis: therapeutic success with methotrexate
10
PubMed. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil
11
CHEST. Methotrexate in the Treatment of Neurosarcoidosis
12
PubMed Central. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective target trial emulated with Swedish real-world data
13
PubMed Central. Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis
14
Archives of Internal Medicine. Role of Liver Function Tests in Detecting Methotrexate-Induced Liver Damage in Sarcoidosis
15
Sarcoidosis Vasculitis and Diffuse Lung Diseases. Methotrexate in Sarcoidosis: Hematologic and Hepatic Toxicity Encountered in a Large Cohort Over a Six Year Period
16
PubMed Central. Flashy lungs and sarcoidosis: not always a sign of disease activity
17
PubMed. Durable remission of cardiac sarcoidosis following discontinuation of methotrexate: A prospective cohort study
18
PubMed Central. Methotrexate treatment efficacy in sarcoidosis might be related to TNF-α polymorphism: real life preliminary study
19
Cureus. A Fulminant Case of Refractory Sarcoidosis Triggered by Infliximab-Neutralizing Antibodies